PharmacoEconomics & Outcomes News

, Volume 799, Issue 1, pp 26–26 | Cite as

NCCN recommends cancer drugs beyond approved indications

Clinical study
  • 6 Downloads

Reference

  1. Wagner J, et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ 2018: k668, No. 360, 7 Mar 2018. Available from: URL: https://doi.org/10.1136/bmj.k668 CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations